These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 23357148)
1. How to optimize lipoprotein apheresis treatment--a second look. Schettler V; Neumann CL; Hagenah GC; Schulz EG; Wieland E Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148 [TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320 [TBL] [Abstract][Full Text] [Related]
3. Actual situation of lipoprotein apheresis in Saxony in 2013. Emmrich U; Hohenstein B; Julius U Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329 [TBL] [Abstract][Full Text] [Related]
4. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Geiss HC; Otto C; Hund-Wissner E; Parhofer KG Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282 [TBL] [Abstract][Full Text] [Related]
5. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on. Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861 [TBL] [Abstract][Full Text] [Related]
6. Effects of lipoprotein apheresis on PCSK9 levels. Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. Morawietz H; Goettsch W; Brux M; Reimann M; Bornstein SR; Julius U; Ziemssen T Atheroscler Suppl; 2013 Jan; 14(1):107-13. PubMed ID: 23357151 [TBL] [Abstract][Full Text] [Related]
8. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels. Lamounier-Zepter V; Look C; Ehrhart-Bornstein M; Bornstein SR; Fischer S; Julius U Atheroscler Suppl; 2013 Jan; 14(1):129-34. PubMed ID: 23357154 [TBL] [Abstract][Full Text] [Related]
9. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment. Schampera S; Fischer S; Weiss N; Julius U Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328 [TBL] [Abstract][Full Text] [Related]
10. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Kroon AA; van't Hof MA; Demacker PN; Stalenhoef AF Atherosclerosis; 2000 Oct; 152(2):519-26. PubMed ID: 10998482 [TBL] [Abstract][Full Text] [Related]
11. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4. Moriarty PM; Luyendyk JP; Gibson CA; Backes JM Am J Cardiol; 2010 Jun; 105(11):1585-7. PubMed ID: 20494666 [TBL] [Abstract][Full Text] [Related]
12. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. Bosch T; Lennertz A; Schenzle D; Dräger J; J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408 [TBL] [Abstract][Full Text] [Related]
13. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. Thiery J; Seidel D Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336 [TBL] [Abstract][Full Text] [Related]
14. One year experience with a low density lipoprotein apheresis system. Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934 [TBL] [Abstract][Full Text] [Related]
17. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre. Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904 [TBL] [Abstract][Full Text] [Related]
18. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia. Tselmin S; Müller G; Schatz U; Julius U; Bornstein SR; Hohenstein B Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840 [TBL] [Abstract][Full Text] [Related]
19. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating. Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934 [TBL] [Abstract][Full Text] [Related]
20. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques. Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Julius U Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]